An interventional study of Plasma p-tau217 and neurofilament light chain results in Alzheimer Blood Biomarkers and Alzheimer's Disease (AD), sponsored by Alzheimercentrum Amsterdam. Recruiting at 8 sites in Netherlands. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Alzheimercentrum Amsterdam · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 32nd largest by planned enrollment of the 119 interventional ones that give a count, is one of 11 that started in 2025, is one of 14 with no phase, reaches primary completion later than 8 of the 26 other live ones, and was the 133rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Netherlands, Australia, Austria and 14 more countries
Ages 18+
Denali Therapeutics Inc. · Sites in Netherlands, United Kingdom
Ages 18–75
Alnylam Pharmaceuticals · Sites in Netherlands, Canada, Spain and 1 more country
Ages 40–80
Bristol-Myers Squibb · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 60–85
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Argentina and 8 more countries
Ages 50–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 45 · Phase 3 47 · Phase 4 1
First in 2000; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 241 across the 119 interventional studies, 502 across the 14 observational. Of the 99 that completed or were terminated, 45 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 133 have an industry lead sponsor. The 10 most frequent:
Alzheimercentrum Amsterdam is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Alzheimercentrum Amsterdam has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Alzheimer Disease with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891716AC Immune SA[18F]ACI-19626 PET in TDP-43 Proteinopathies | 2026-11 |
| NCT07680335Alzheimercentrum AmsterdamThe BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07328451Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | 2027-02 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.
Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.
This study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood-based biomarker results are not disclosed to the physician and/or patient, patient receives usual care and diagnostics
In addition to usual care and diagnostics, blood-based biomarker results are sent to the physician who can disclose the results to the patient
Diagnostic Test: Plasma p-tau217 and neurofilament light chain results
Results of the Quanterix Simoa ALZpath p-tau217 and Quanterix Simoa NfL assay.
Time from baseline to final diagnosis
The time from baseline visit to final diagnosis will be reported in days.
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Change in diagnosis
Comparison between the diagnosis (syndrome diagnosis and etiology) before and after BBM testing. Change in diagnosis will be reported as yes/no.
Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months
Change in physician's confidence in diagnosis
Comparison between physician's confidence in diagnosis before and after BBM testing within the intervention group. Physician's confidence will be measured on a 7-point Likert scale, with 1 being very uncertain and 7 being very certain.
Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months
Difference between the intervention group and the control group in use and timing of ancillary tests
Use of ancillary tests (yes/no), including neuropsychological evaluation, brain CT, brain MRI, CSF biomarker analysis, amyloid PET, FDG PET, DaT-SPECT, EEG/MEG, genetic testing, and speech therapy consultation. If performed, the timing in days from enrollment will be reported.
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Concordance of BBM results with the presence of AD pathology according to CSF or amyloid PET
Concordance will be defined as the percentage of BBM results (positive or negative) that is concordant with CSF or amyloid PET results (positive or negative).
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Difference between the intervention group and the control group in patient management: follow-up duration
Duration of patient follow-up (reported in days)
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Difference between the intervention group and the control group in patient management: referral
Referral to another specialist or center (yes/no)
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Difference between the intervention group and the control group in patient management: prescription of medication
Prescription of medication (yes / no; if yes which medication)
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Usefulness of AD BBMs per case as perceived by the physician
In the intervention group: Usefulness as perceived by the physician measured on a 5-point Likert scale with 1 being extremely unuseful and 5 being extremely useful. In the control group: Hypothetical usefulness (yes/no/maybe) as perceived by the physician in case the BBM results would have been received. In all cases: Desireability of the blood test being performed (yes/no) as perceived by the physician prior to receiving BBM results.
Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months
Patients' motivation for participation
Participants will be asked to indicate their motivation for participation.
Time frame: After the blood test is performed, assessed up to 3 months
Patients' experience with receiving or not receiving BBM results
Intervention group: Experience of receiving BBM results will be assessed by asking participants: * Whether not receiving the results would have been preferred (yes/no/I do not know) * Whether receiving the results had positive consequences (yes/no) * Whether receiving the results had negative consequences (yes/no) In the control group: experience of not receiving BBM results will be assessed by asking participants: \- Whether receiving the results would have been preferred (yes/no/I do not know)
Time frame: After the blood test is performed, assessed up to 3 months
Patient's understanding of the BBM results
Participant's understanding will be assessed by asking participants whether the diagnosis changed after receiving BBM results. If yes, participants will be asked to indicate the initial diagnosis. Additionally, participants will be asked to explain, in their own words, what the BBM results meant.
Time frame: After the blood test is performed, assessed up to 3 months
Patients' satisfaction with the provision of information
In case the results were disclosed to the patient: Satisfaction will be assessed by rating their agreement with 2 statements on a 5-point agree/disagree scale with 1 being strongly disagree and 5 being strongly agree.
Time frame: After the blood test is performed, assessed up to 3 months
Patients' satisfaction with the decision to participate
In all cases: Satisfaction will be assessed by asking participants to rate their agreement with 4 statements on a 5-point decision regret scale with 1 being strongly disagree and 5 being strongly agree.
Time frame: After the blood test is performed, assessed up to 3 months
Cognitive performance measured by the MOCA
Total scores of the Montreal Cognitive Assessment (MoCA) will be registered, if performed during clinical work-up. Scores range from 0 to 30.
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Cognitive performance measured by the MMSE
Total scores of the Mini-Mental State Examination (MMSE) will be registered, if performed during clinical work-up. Scores range from 0 to 30.
Time frame: From enrolment to final diagnosis, assessed up to 100 months
Survival
Information on survival will be requested from Statistics Netherlands (Centraal Bureau voor de Statistiek; CBS), provided informed consent has been given for this (optional / separate question in ICF).
Time frame: Up to 10 years after study completion
Plan to share: Undecided — There are plans to share IPD through the ADDI platform, however a contract or data sharing agreement has not yet been established. Therefore it is not yet clear which specific IPD will be shared.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 15 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alzheimercentrum Amsterdam